AGI-5198

Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD⁺) and NAD phosphate (NADP⁺)-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing a-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.¹ The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).^2,3,4 AGI-5198 is a potent, selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC₅₀ values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC₅₀s > 100 μM).⁵ AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2‑HG production in HT1080 and U87MG cells with IC₅₀ values of 0.48 and 0.07 µM, respectively.⁶ In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts.⁵ Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.⁵

WARNING This product is not for human or veterinary use.

1. Turcan, S., Rohle, D., Goenka, A., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390), 479-483 (2012).

2. Reitman, Z.J., and Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 102(13), 932-941 (2010).

3. Dang, L., White, D.W., Gross, S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274), 739-744 (2009).

4. Koivunen, P., Lee, S., Duncan, C.G., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483(7390), 484-488 (2012).

5. Rohle, D., Popovici-Muller, J., Palaskas, N., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation on glioma cells. Science 340(6132), 626-630 (2013).

6. Popovici-Muller, J., Saunders, J.O., Salituro, F.G., et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 3(10), 850-855 (2012).